BioSpace News Archive

KSQ Therapeutics today named Micah Benson, PhD as the new Chief Scientific Officer (CSO) and announced the addition of a new Chief Technology Officer (CTO), Tom Leitch, to the KSQ leadership team.

Zivo Bioscience, Inc. today issued the following letter to shareholders from its Chairman, President and Chief Executive Officer, John Payne.

Mainstay Medical Holdings plc announced today that the National Institute for Health and Care Excellence (NICE), a public body of the Department of Health that carries out evidence-based health technology assessments by independent committees, has issued a recommendation that ReActiv8® Restorative Neurostimulation™ can be used in the National Health Service in the U.K., with special arrangements for clinical governance, consent, and audit or research.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022.

Biotech and medical AI innovator Surge announced a $2.6 million round co-led by HCVC, a global early-stage fund dedicated to high-potential technology startups, and Boutique Venture Partners, a leading fund based in the Silicon Valley.

PDS Biotechnology Corporation announced PDS Biotech granted nonstatutory stock options to Amber King, PDS Biotech’s Clinical Trial Assistant, to purchase 5,000 shares of PDS Biotech common stock.

Palisade Bio, Inc. announced that it had made equity grants to two new employees under its 2021 Inducement Plan.

According to Nova one advisor, the global Hemodialysis and Peritoneal Dialysis market was valued at USD 88.20 billion in 2021 and it is expected to hit around USD 156.63 billion by 2030 with a CAGR of 6.65% during the forecast period 2022 to 2030.

InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”) announced today the appointment of R. Rimmy Malhotra, a new independent director to InfuSystem’s Board of Directors, effective September 20, 2022.

According to Nova one advisor, the global Stem Cell Therapy market size was estimated at USD 9.87 billion in 2021 and is expected to surpass around USD 31.41 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 13.73% during the forecast period 2022 to 2030.